Bispecific T cell engagers
Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
1. A polypeptide comprising two antigen binding fragments of anti-DLL3 antibodies,
wherein the polypeptide comprises:
a first polypeptide chain comprising an antigen binding fragment of a first anti-DLL3 antibody in svfc form, wherein the antigen binding fragment of the first anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:7, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:14, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:31, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:40, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:47;
a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, wherein the heavy chain of the second anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:16, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:24; and
a third polypeptide chain comprising a light chain of the second anti-DLL3 antibody, wherein the light chain of the second anti-DLL3 antibody comprises a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:33, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:43, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:49,
wherein the first anti-DLL3 antibody and the second anti-DLL3 antibody bind to different epitopes of DLL3.
2. The polypeptide of claim 1 , further comprising an antigen binding fragment of an anti-CD3 antibody in the first polypeptide chain, wherein the anti-CD3 antibody comprises a heavy chain variable region comprising SEQ ID NO:256 and a light chain variable region comprising SEQ ID NO:261.
3. The polypeptide of claim 1 , wherein the the two antigen binding fragments of the anti-DLL3 antibodies are humanized.
4. A composition comprising:
a) the polypeptide of claim 1 , and
b) a pharmaceutically acceptable carrier.
5. A method of activating T-cells against DLL3 expressing cells in a subject, comprising the step of administering to the subject an effective amount of the polypeptide of claim 1 .
6. A polypeptide comprising:
a first polypeptide chain comprising an antigen binding fragment of a first anti-DLL3 antibody comprising a heavy chain variable region comprising SEQ ID NO:72 and a light chain variable region comprising SEQ ID NO:76,
a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, wherein the heavy chain of the second anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 16, and heavy chain CDR3 comprising the amino acid sequence of SE ID NO:24; and
a third polypeptide chain comprising a light chain of the second anti-DLL3 antibody, wherein the light chain of the second anti-DLL3 antibody con rises a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:33, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:43, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:49,
wherein the first anti-DLL3 antibody and the second anti-DLL3 antibody bind to different epitopes of DLL3.
7. The polypeptide of claim 6 , wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:347, wherein the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:276, and wherein the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:297.
8. A method of activating T-cells against DLL3 expressing cells in a subject, comprising the step of administering to the subject an effective amount of the polypeptide of claim 6 .
9. A polypeptide comprising an antigen binding fragment of an anti-CD3 antibody and two antigen binding fragments of anti-DLL3 antibodies, wherein the polypeptide comprises:
a first polypeptide chain comprising:
(1) an antigen binding fragment of a first anti-DLL3 antibody in svfc form, wherein the antigen binding fragment of a first anti-DLL3 antibody in svfc form comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:7, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:14, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:31, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:40, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:47; and
(2) an antigen binding fragment of an anti-CD3 antibody in scfv form, wherein the antigen binding fragment of an anti-CD3 antibody in scfv form comprises a heavy chain variable region comprising SEQ ID NO:256 and a light chain variable region comprising SEQ ID NO:261;
a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, wherein the heavy chain of the second anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:16, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:24; and
a third polypeptide chain comprising a light chain of the second anti-DLL3 antibody, wherein the light chain of the second anti-DLL3 antibody comprises a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:33, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:43, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:49,
wherein the first anti-DLL3 antibody and the second anti-DLL3 antibody bind to different epitopes of DLL3.
10. A polypeptide comprising:
a first polypeptide chain comprising:
(1) an antigen binding fragment of a first anti-DLL3 antibody in svfc form comprising a heavy chain variable region comprising SEQ ID NO:72 and a light chain variable region comprising SEQ ID NO:76; and
(2) an antigen binding fragment of an anti-CD3 antibody in scfv form comprising a heavy chain variable region comprising SEQ ID NO:256 and a light chain variable region comprising SEQ ID NO:261;
a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, wherein the heavy chain of the second anti-DLL3 antibody comprises a heavy chain variable region comprising SEQ ID NO:58; and
a third polypeptide chain comprising a light chain of the second anti-DLL3 antibody, wherein the light chain of the second anti-DLL3 antibody comprises a light chain variable region comprising SEQ ID NO:78.